- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04473378
Glucose Monitoring During Chemotherapy
January 10, 2024 updated by: Melissa K Accordino, Columbia University
Pilot Study of Glucose Monitoring to Determine Rates of Hyperglycemia During Chemotherapy for Early Stage Breast Cancer
This is a research study to look at blood sugar changes during chemotherapy using a continuous blood sugar monitoring device.
The device uses patches that attach to the skin on the back of the arm to measure blood sugar changes for the duration of the chemotherapy course.
Each patch lasts for about 2-weeks.
During chemotherapy visits, new patches will be placed and will be worn until the chemotherapy course is complete.
Participants will be in this study for 6 months.
Approximately 50 patients will be enrolled in this study.
Study Overview
Status
Active, not recruiting
Conditions
Intervention / Treatment
Detailed Description
This is a prospective observational cohort study monitoring trends in glucose in patients with early stage breast cancer treated with neoadjuvant or adjuvant chemotherapy.
Patients will wear a noninvasive glucose monitoring sensor, the Freestyle Libre Pro for the duration of chemotherapy.
The primary goal of this trial is to evaluate the prevalence of hyperglycemia in patients with early-stage breast cancer during neoadjuvant/adjuvant chemotherapy.
Fifty patients will be enrolled.
During each chemotherapy encounter, subjects will have their glucose sensor scanned in order to download subjects' glucose data.
If the sensor has become no longer adherent to the participant's skin, participants will bring the sensor with them to the chemotherapy infusion center to be scanned.
During each chemotherapy encounter, the Free Style Libre sensor will be replaced by the study team.
Participants who receive chemotherapy every three weeks will be asked to come in 10-14 days after their chemotherapy infusion to replace the sensor.
The sensors will be worn through completion of chemotherapy (the duration will vary based on the individual's chemotherapy regimen).
Patients will have fructosamine, a glucose biomarker, and serum creatinine testing at baseline and every 3 weeks (weeks 3, 6, 9, 12, 15, 18, 21, 24) until week 24 (note: week 15, 18, and 21 are optional).
Patients will have additional glucose biomarker testing (hemoglobin a1c, glucose, and insulin [fasting preferred]) at baseline, week 12 and week 24.
Patients will also complete questionnaires assessing for symptoms of chemotherapy induced peripheral neuropathy, quality of life, and fatigue at baseline, week 12 and week 24.
Visits will be conducted within the below specified windows forbidding unexpected circumstances such as missed appointments or loss to follow-up.
Study Type
Observational
Enrollment (Actual)
22
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
New York
-
New York, New York, United States, 10032
- Herbert Irving Pavilion
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Sampling Method
Probability Sample
Study Population
Patients with early stage breast cancer.
Description
Inclusion Criteria:
- Age ≥18 years
- History of stage I-III breast cancer
- Patient scheduled to receive adjuvant or neoadjuvant chemotherapy
- Signed informed consent
Exclusion Criteria:
- Current treatment with insulin
- Current treatment with non-topical steroids, with the exception of steroid treatment as a supportive chemotherapy medication
- Inability to provide informed consent
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
FreeStyle Libre sensor cohort
Patients with early stage breast cancer will have their blood glucose levels monitored by the Freestyle libre pro sensor.
|
The device uses patches that attach to the skin on the back of the arm to measure blood sugar changes for the duration of the chemotherapy course.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Prevalence of hyperglycemia
Time Frame: 24 weeks
|
assess the prevalence of HG, defined as the number of participants who have ≥1 glucose value of ≥140 mg/dL at any point during chemotherapy
|
24 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Prevalence of impaired glucose tolerance at baseline in nondiabetic patients.
Time Frame: Baseline
|
Prevalence of glucose intolerance will be defined as a hemoglobin a1c >5.7% at baseline in nondiabetic patients The American Diabetes Association classifies individuals with a hemoglobin A1c level of 5.7-6.4% as having an increased risk of DM.The American Diabetes Association classified individuals with a hemoglobin A1c level of 6.5% or higher on two separate occasions as having a diagnosis of DM.
|
Baseline
|
Patient-Reported Outcomes Measurement Information System (PROMIS)-29
Time Frame: Baseline, week 12, and week 24
|
The PROMIS-29 consists of 29 questions to measure global quality of life, including four questions from each of the following domains: anxiety, depression, fatigue, pain interference, physical function, sleep disturbance, satisfaction with participation in social roles, ability to participate in social roles and activities; it includes a single pain intensity item.
|
Baseline, week 12, and week 24
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Melissa Accordino, MD, Columbia University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 31, 2019
Primary Completion (Estimated)
August 1, 2024
Study Completion (Estimated)
August 1, 2024
Study Registration Dates
First Submitted
July 13, 2020
First Submitted That Met QC Criteria
July 13, 2020
First Posted (Actual)
July 16, 2020
Study Record Updates
Last Update Posted (Actual)
January 12, 2024
Last Update Submitted That Met QC Criteria
January 10, 2024
Last Verified
January 1, 2024
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- AAAS3402
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hyperglycemia
-
Mayo ClinicCompletedHospital Hyperglycemia | Post-transplant HyperglycemiaUnited States
-
Zealand University HospitalNot yet recruitingStress Hyperglycemia | Postoperative Hyperglycemia
-
University of CopenhagenUnknownSurgery--Complications | Hyperglycemia Stress | Hyperglycemia Steroid-inducedDenmark
-
University of LeedsCompletedEffect of Food on Postprandial HyperglycemiaUnited Kingdom
-
Emory UniversityNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National...RecruitingHyperglycemia StressUnited States
-
Loughborough UniversityUniversity of BedfordshireCompletedPostprandial HyperglycemiaUnited Kingdom
-
Centre Hospitalier Universitaire de BesanconEli Lilly and Company; AstraZenecaCompleted
-
Medical University of ViennaCompleted
-
Addis Ababa UniversityCompletedHyperglycemia, Postprandial
-
University of Eastern FinlandFinnsugar LtdCompletedHyperglycemia, PostprandialFinland
Clinical Trials on FreeStyle Libre Pro
-
Centre Hospitalier Universitaire de BesanconNot yet recruitingDiabetes | Breast CancerFrance
-
The Leeds Teaching Hospitals NHS TrustUnknownDiabetes MellitusUnited Kingdom
-
Odense University HospitalZealand University HospitalNot yet recruiting
-
Klick Inc.Mittal Global Clinical Trial ServicesCompletedHealthy | Type 2 Diabetes MellitusCanada
-
University Hospital, MontpellierRecruitingAcute Coronary Syndrome | Glycemic Variability | Cardiovascular Event | Continuous Glucose MeasurementFrance
-
Palo Alto Medical FoundationEmory University; Abbott Diabetes CareRecruiting
-
Portsmouth Hospitals NHS TrustCompletedDiabetes Mellitus | Surgical Procedure, UnspecifiedUnited Kingdom
-
Abbott Diabetes CareCompleted
-
University of Colorado, DenverActive, not recruitingHematopoietic Stem Cell TransplantationUnited States